Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
Asianet Newsable on MSN
CRSP, VRTX stocks surge as FDA clears Casgevy for children ages 2 and up
The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD ...
Zacks Investment Research on MSN
Vertex gets FDA nod for expanded use of Casgevy in SCD & TDT
Vertex Pharmaceuticals VRTX announced that the FDA has approved its one-shot gene therapy, Casgevy (exagamglogene autotemcel) ...
The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher ...
The Food and Drug Administration approved the use of Vertex Pharmaceuticals's sickle cell disease treatment, Casgevy, for patients as young as two years old. The agency said Wednesday that it issued a ...
Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' gene therapy in children as young as two with ...
A former GSK and Vertex exec launched Purely Golden Foods, a fresh dog food company that tests each batch like pharmaceutical ...
KUALA LUMPUR, Malaysia, May 8, 2026 /PRNewswire/ -- Vertex Mastery, a business strategy consulting firm specialising in SME scale-up across Southeast Asia, today announced the launch of the next phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results